Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating recombinant human C1 esterase inhibitor for early antibody-mediated rejection in kidney transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Graft Rejection, Kidney Transplantation | Phase 2 | Status: WITHDRAWN